Emerging Insights: Vaccine Efficacy and Clinical Dynamics in the Context of Multiple Pathogen Exposures

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 1107

Special Issue Editors

E-Mail Website
Guest Editor
1. Institute of Medical Biology, Immunology, and Parasitology, University Hospital Bonn, Bonn, Germany
2. Department of Biochemistry and Cell Biology, Faculty of Science, University of Abomey-Calavi, Godomey, Benin
Interests: tropical Infections; coinfections; epidemiology; SARS-CoV-2; COVID-19; vaccines

E-Mail Website
Guest Editor
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
Interests: helminths; immune regulation; T and B cell immunology; antibody production; COVID-19

Special Issue Information

Dear Colleagues,

The COVID-19 pandemic, which was triggered by the novel coronavirus SARS-CoV-2, led to a global health crisis that claimed millions of lives. Despite its large population and limited healthcare resources, the African continent experienced less impacts than initially predicted. This observation raises questions about the role of prevalent tropical diseases in Africa in shaping the trajectory of the pandemic. The interplay between tropical infections and COVID-19 may have affected disease outcomes and the efficacy of vaccinations. 

Beyond the scope of COVID-19, this Special Issue aims to discuss the interactions between endemic infections in tropical countries and the course of disease. We are particularly interested in understanding how these tropical co-infections modulate the course and treatment of these diseases. We seek contributions that examine the role of vaccines and tropical co-infections in epidemiology, clinical diagnostics, and disease management.

We encourage submissions that offer novel insights into these complex interactions and their implications for public health. We welcome original research, brief reports, systematic reviews, letters to the editor, opinion pieces, and perspectives.

Our goal is to foster a comprehensive understanding of these critical issues, and we believe that your contribution can significantly aid this endeavor. We look forward to your submissions.

Dr. Tomabu Adjobimey
Prof. Dr. Henry Mwandumba
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • vaccines
  • tropical infections
  • coinfections
  • epidemiology
  • SARS-CoV-2
  • COVID-19
  • disease modulation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 1754 KiB  
Enhancement of SARS-CoV-2 mRNA Vaccine Efficacy through the Application of TMSB10 UTR for Superior Antigen Presentation and Immune Activation
by Xiaoyan Ding, Yuxin Zhou, Jiuxiang He, Jing Zhao and Jintao Li
Vaccines 2024, 12(4), 432; https://doi.org/10.3390/vaccines12040432 - 17 Apr 2024
Viewed by 697
The development of effective vaccines against SARS-CoV-2 remains a critical challenge amidst the ongoing global pandemic. This study introduces a novel approach to enhancing mRNA vaccine efficacy by leveraging the untranslated region (UTR) of TMSB10, a gene identified for its significant mRNA abundance [...] Read more.
The development of effective vaccines against SARS-CoV-2 remains a critical challenge amidst the ongoing global pandemic. This study introduces a novel approach to enhancing mRNA vaccine efficacy by leveraging the untranslated region (UTR) of TMSB10, a gene identified for its significant mRNA abundance in antigen-presenting cells. Utilizing the GEO database, we identified TMSB10 among nine genes, with the highest mRNA abundance in dendritic cell subtypes. Subsequent experiments revealed that TMSB10’s UTR significantly enhances the expression of a reporter gene in both antigen-presenting and 293T cells, surpassing other candidates and a previously optimized natural UTR. A comparative analysis demonstrated that TMSB10 UTR not only facilitated a higher reporter gene expression in vitro but also showed marked superiority in vivo, leading to enhanced specific humoral and cellular immune responses against the SARS-CoV-2 Delta variant RBD antigen. Specifically, vaccines incorporating TMSB10 UTR induced significantly higher levels of specific IgG antibodies and promoted a robust T-cell immune response, characterized by the increased secretion of IFN-γ and IL-4 and the proliferation of CD4+ and CD8+ T cells. These findings underscore the potential of TMSB10 UTR as a strategic component in mRNA vaccine design, offering a promising avenue to bolster vaccine-induced immunity against SARS-CoV-2 and, potentially, other pathogens. Full article
Show Figures

Figure 1

Back to TopTop